A Single-centre, Randomised, Double-blind, Placebo-controlled, Multiple-dose Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects
Latest Information Update: 10 Nov 2020
At a glance
- Drugs Semaglutide (Primary)
- Indications Atherosclerosis; Liver cirrhosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity; Peripheral arterial disorders; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 07 Nov 2020 Results assessing the pharmacokinetics, safety and tolerability of semaglutide in healthy Chinese subjects, published in the Advances in Therapy
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 08 Aug 2018 Status changed from active, no longer recruiting to completed.